Maternal RSV Vaccine Linked to Lower Risk of Infant Hospitalization

— "This is real protection, and it really applies to all comers," researcher says

June 8, 2026

• 3 min read

Data from the previous MATISSE trial showed that the maternal RSV vaccine was efficacious against RSV-associated hospitalization in infants, but real-world effectiveness data were needed.In a retrospective case-control study, the estimated vaccine effectiveness with maternal RSV prefusion F was 67.6% against RSV-associated acute respiratory illness hospitalization among infants ages 90 days and younger.Among infants ages 30 days or younger, estimated vaccine effectiveness against RSV-associated acute respiratory illness hospitalization was 74.2%.

Maternal respiratory syncytial virus (RSV) vaccination during pregnancy was effective at preventing infants from being hospitalized with RSV-associated acute respiratory illness (ARI) in a real-world setting, according to a retrospective case-control study.